ATE465986T1 - Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck - Google Patents

Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck

Info

Publication number
ATE465986T1
ATE465986T1 AT06717964T AT06717964T ATE465986T1 AT E465986 T1 ATE465986 T1 AT E465986T1 AT 06717964 T AT06717964 T AT 06717964T AT 06717964 T AT06717964 T AT 06717964T AT E465986 T1 ATE465986 T1 AT E465986T1
Authority
AT
Austria
Prior art keywords
cyclopentanones
treatment
substituted cyclopentanes
eye hypertension
hypertension
Prior art date
Application number
AT06717964T
Other languages
English (en)
Inventor
David Old
Todd Gac
Vinh Ngo
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc filed Critical Allergan Inc
Application granted granted Critical
Publication of ATE465986T1 publication Critical patent/ATE465986T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/58—Unsaturated compounds containing ether groups, groups, groups, or groups
    • C07C59/72—Unsaturated compounds containing ether groups, groups, groups, or groups containing six-membered aromatic rings and other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/74—Unsaturated compounds containing —CHO groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/90—Unsaturated compounds containing keto groups containing singly bound oxygen-containing groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/52—Esters of acyclic unsaturated carboxylic acids having the esterified carboxyl group bound to an acyclic carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/734—Ethers
    • C07C69/736—Ethers the hydroxy group of the ester being etherified with a hydroxy compound having the hydroxy group bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
    • C07C69/66—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety
    • C07C69/73—Esters of carboxylic acids having esterified carboxylic groups bound to acyclic carbon atoms and having any of the groups OH, O—metal, —CHO, keto, ether, acyloxy, groups, groups, or in the acid moiety of unsaturated acids
    • C07C69/738—Esters of keto-carboxylic acids or aldehydo-carboxylic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
AT06717964T 2005-01-14 2006-01-10 Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck ATE465986T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US64406905P 2005-01-14 2005-01-14
PCT/US2006/000831 WO2006076370A2 (en) 2005-01-14 2006-01-10 Substituted cyclopentanes or cyclopentanones for the treatment of ocular hypertensive conditions

Publications (1)

Publication Number Publication Date
ATE465986T1 true ATE465986T1 (de) 2010-05-15

Family

ID=36678136

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06717964T ATE465986T1 (de) 2005-01-14 2006-01-10 Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck

Country Status (20)

Country Link
US (1) US7635716B2 (de)
EP (1) EP1846354B1 (de)
JP (1) JP5060311B2 (de)
KR (1) KR101227808B1 (de)
CN (1) CN101102989B (de)
AR (1) AR052876A1 (de)
AT (1) ATE465986T1 (de)
AU (1) AU2006205029B2 (de)
BR (1) BRPI0605926A2 (de)
CA (1) CA2593661A1 (de)
DE (1) DE602006013945D1 (de)
DK (1) DK1846354T3 (de)
ES (1) ES2343430T3 (de)
HK (1) HK1114601A1 (de)
IL (1) IL184025A (de)
MX (1) MX2007008188A (de)
NZ (1) NZ555945A (de)
TW (1) TWI379696B (de)
WO (1) WO2006076370A2 (de)
ZA (1) ZA200704739B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7799336B2 (en) 2004-04-30 2010-09-21 Allergan, Inc. Hypotensive lipid-containing biodegradable intraocular implants and related methods
WO2007005176A1 (en) 2005-06-29 2007-01-11 Allergan, Inc. Pyrrolidinones for the treatment of glaucoma and ocular hypertension
US7429669B2 (en) 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds
BRPI0714709A2 (pt) * 2006-07-10 2013-02-26 Allergan Inc compostos terapÊuticos, bem como uso dos mesmos
US20080015219A1 (en) * 2006-07-11 2008-01-17 Allergan, Inc. Therapeutic compounds
US7507817B2 (en) 2006-11-17 2009-03-24 Allergan, Inc. Prostaglandin prodrugs
AU2008208032B2 (en) * 2007-01-22 2013-03-07 Allergan, Inc. Substituted arylcylopentenes as therapeutic agents
NZ582705A (en) * 2007-07-03 2012-06-29 Allergan Inc Therapeutic substituted cyclopentanes for reducing intraocular pressure
CA2706879A1 (en) * 2007-11-29 2009-06-11 Robert M. Burk Substituted cyclopentanes having prostaglandin activity
WO2009132093A2 (en) * 2008-04-24 2009-10-29 Allergan, Inc. Substituted arylcyclopentenes as therapeutic agents
KR102307281B1 (ko) 2013-10-31 2021-09-29 알레간 인코포레이티드 프로스타마이드-함유 안구내 삽입물 및 그것의 사용 방법
TW201613864A (en) 2014-02-20 2016-04-16 Takeda Pharmaceutical Novel compounds
WO2015175544A1 (en) 2014-05-12 2015-11-19 Allergan, Inc. Quaternary ammonium alkyl esters of prostanoid derivatives as stable prodrugs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3980700A (en) 1971-10-07 1976-09-14 G. D. Searle & Co. Prostaglandin intermediates and optically active isomers thereof
SE436037B (sv) * 1976-04-30 1984-11-05 Roussel Uclaf Sett att framstella nya 11-desoxi-prostaglandin-f?712-derivat
US5510383A (en) * 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
DK0951282T3 (da) 1996-12-20 2008-07-14 Pfizer Forebyggelse og behandling af skeletlidelse med EP2-receptorsubtype-selektive prostaglandin E2-agonister
WO1998058911A2 (en) 1997-06-23 1998-12-30 Pfizer Inc. Prostaglandin agonists
US6437146B1 (en) 1998-09-25 2002-08-20 Fujisawa Pharmaceutical Co., Ltd. Oxazole compounds as prostaglandin e2 agonists or antagonists
EP1108426A3 (de) 1999-12-02 2002-10-02 Pfizer Products Inc. Anwendung von Prostaglandinagonisten zur Behandlung der Erektionstörungen und Impotenz
US6291522B1 (en) * 2000-09-27 2001-09-18 Allergan Sales, Inc. Cyclopentane heptan(ENE)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents
ATE305463T1 (de) 2001-11-05 2005-10-15 Allergan Inc Omega-zykloalkyl 17-heteroaryl prostaglandin-e2- analoga als ep2-rezeptoragonisten
JP4547912B2 (ja) 2002-03-05 2010-09-22 小野薬品工業株式会社 ８−アザプロスタグランジン誘導体化合物およびその化合物を有効成分として含有する薬剤
WO2004089411A1 (ja) 2003-04-03 2004-10-21 Ono Pharmaceutical Co., Ltd. 脊柱管狭窄症治療剤
US7323591B2 (en) * 2006-01-10 2008-01-29 Allergan, Inc. Substituted cyclopentanes or cyclopentanones as therapeutic agents
US7429669B2 (en) * 2006-06-20 2008-09-30 Allergan, Inc. Therapeutic compounds

Also Published As

Publication number Publication date
WO2006076370A2 (en) 2006-07-20
JP5060311B2 (ja) 2012-10-31
JP2008526970A (ja) 2008-07-24
CN101102989A (zh) 2008-01-09
KR101227808B1 (ko) 2013-01-30
AR052876A1 (es) 2007-04-11
NZ555945A (en) 2011-01-28
IL184025A0 (en) 2008-12-29
WO2006076370A3 (en) 2007-01-11
BRPI0605926A2 (pt) 2009-05-26
TW200714312A (en) 2007-04-16
DE602006013945D1 (de) 2010-06-10
DK1846354T3 (da) 2010-08-16
KR20070094919A (ko) 2007-09-27
CN101102989B (zh) 2011-11-16
TWI379696B (en) 2012-12-21
MX2007008188A (es) 2007-08-07
HK1114601A1 (en) 2008-11-07
ZA200704739B (en) 2009-10-28
CA2593661A1 (en) 2006-07-20
AU2006205029B2 (en) 2012-09-06
EP1846354A2 (de) 2007-10-24
AU2006205029A1 (en) 2006-07-20
WO2006076370B1 (en) 2007-02-22
ES2343430T3 (es) 2010-07-30
EP1846354B1 (de) 2010-04-28
US7635716B2 (en) 2009-12-22
US20080058414A1 (en) 2008-03-06
IL184025A (en) 2012-09-24

Similar Documents

Publication Publication Date Title
ATE465986T1 (de) Substituierte cyclopentane oder cyclopentanone zur behandlung von augenhochdruck
ATE429218T1 (de) Pinolensäure zur behandlung von übergewicht
ATE369333T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE375977T1 (de) Sulfonamidderivate zur behandlung von krankheiten
ATE434620T1 (de) Dihydrothienopyrimidine zur behandlung von entzündlichen erkrankungen
DE602006019560D1 (de) 2-cyanobenzolsulfonamidverbindungen zur behandlung von samen
ATE493986T1 (de) Diarylharnstoffe zur behandlung von pulmonaler hypertonie
ATE512663T1 (de) Kombination zur behandlung von erkrankungen mit zellproliferation
DE602004028763D1 (de) Te zur behandlung von virenerkrankungen
ATE521365T1 (de) Kinin-antagonisten zur behandlung von blasenfunktionsstörung
ATE496911T3 (de) Piperazinsubstituierte benzothiophene zur behandlung von geisteskrankheiten
ATE550329T1 (de) Heterobicyclische sulfonamidderivate zur behandlung von diabetes
DE502005010499D1 (de) Implantat zur Behandlung von Fettsucht
ATE512948T1 (de) Biphenyl-sulfonyl- und phenyl-heteroaryl-sulfonyl-modulatoren des histamin-h3-rezeptors zur behandlung von damit verbundenen erkrankungen
DE602006020201D1 (de) Aerobes-anaerobes Verfahren zur Behandlung von organisch belasteten Abwässern
ATE429222T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
DE602006007323D1 (de) VERWENDUNG VON BAFF ZUR BEHANDLUNG Th2-INDUZIERTER LEIDEN
DE602006003094D1 (de) 4-phenyl-5-oxo-1,4,5,6,7,8-hexahydrochinolin-derivate zur behandlung von unfruchtbarkeit
DE602005016141D1 (de) S-mirtazapin zur behandlung von hitzewallungen
DE502005002324D1 (de) Reaktor zur behandlung hochviskoser kunststoffschmelzen
ATE504297T1 (de) Visnadin zur behandlung von kopfhautjucken
ATE429221T1 (de) Medikamente zur behandlung oder prävention fibrotischer krankheiten
ATE503752T1 (de) Sulfamide alsendothelinrezeptorantagonsiten zur behandlung von herzkreislauferkrankungen
DK1940447T3 (da) Behandling af neurodegenrative lidelser
DE602006010364D1 (de) Pharmazeutikum zur prävention oder behandlung von metabolischer knochenkrankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties